Opinion|Videos|July 15, 2024
Dr Voss Application of Updated KEYNOTE-564 Data
Martin Voss, MD, elaborates on the impact of the KEYNOTE-564 trial and its recently presented data on the management of renal cell carcinoma, highlighting how these findings have influenced treatment decisions and patient care strategies.
Advertisement
Episodes in this series
- Now that many patients are getting adjuvant pembrolizumab based on KEYNOTE-564 and recent OS data presented(KEYNOTE-564 update (
Choueiri et al., ASCO GU 2024 Abstract LBA359 ):
- How does that change your management for patients that progress?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week.
Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
The FDA granted fast track designation to PSV359 for locally advanced unresectable or metastatic FAP-positive solitary fibrous tumors.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Surgeons at the UC San Francisco have performed over 25,000 robotically assisted minimally invasive surgeries.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
VIR-5500 Receives FDA Fast Track Designation in mCRPC
3
Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma
4
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
5